Business
European Respiratory Society Congress Attendance
Nuformix PLC announced its attendance at the European Respiratory Society Congress commencing on September 28, 2025, in Amsterdam, where it will present new insights on its NXP002 lead program, an inhaled treatment for idiopathic pulmonary fibrosis. The company's in-depth pharmacology review, leveraging human and AI methodologies, demonstrated NXP002's potential to regulate four specific pathways that drive fibrotic disease, including the TGF-ß, WNT/ß-catenin, and NLRP3 pathways. The outputs also illustrate consistent translation from cell-based studies to clinical studies across multiple fibrotic organs, including the lung, in the resolution of extra cellular matrix deposition. The company has summarized its findings in a new document 'NXP002 Pathway and Translation Update' which is available via a provided link. Disclaimer*
About this update from Nuformix Plc
[{"type":"text","content":"\n\nREACH\n \n25 September 2025\n \nNuformix plc\n \n(\"Nuformix\" or the \"Company\")\n \nAttendance at European Respiratory Society Congress, Amsterdam 2025\n \nNuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce it will be attending the European Respiratory Society (\"ERS\") Congress commencing from 28 September 2025 in Amsterdam. \n \nAt the ERS Congress the Company will share new insights relating to its NXP002 lead programme - an inhaled treatment for idiopathic pulmonary fibrosis and related respiratory conditions. Following an in-depth pharmacology review, leveraging human and AI-methodologies, the pathways associated with disease progression in fibrotic diseases in which NXP002 has demonstrated both activity and clinical translation have been assessed across multiple organs.\n \nThe resulting outputs allow clear demonstration of NXP002's potential to regulate four specific pathways that drive fibrotic disease. This includes core pathways, such as the TGF- ß pathway, but also evidences regulation of the WNT/ß-catenin and NLRP3 pathways, which are emerging as key disease progression pathways requiring suppression. The outputs also illustrate consistent translation from cell-based studies to clinical studies across multiple fibrotic organs, including the lung, in the resolution of extra cellular matrix deposition.\n \nThe Company has summarised its findings in a new document 'NXP002 Pathway and Translation Update' which is available via the following link http://www.rns-pdf.londonstockexchange.com/rns/7219A_1-2025-9-24.pdf and will be published on the Company's website.\n \nThe Company continues to have ongoing discussions with potential development partners and will further showcase NXP002 at the ERS Congress.\n \nDr Dan Gooding, Executive Director, Nuformix, said: \"We are very much looking forward to attending the ERS Congress in Amsterdam. We believe that inhalation is now a validated and attractive treatment option for IPF and PPF. We also believe that delivering improved treatments to patients requires regulation of multiple disease pathways involved in fibrosis progression, given the complexity of the underlying disease. Our recent analysis allows us...